Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions

RIDRUEJO, EZEQUIEL; DI LELLO, FEDERICO ALEJANDRO; PERESON, MATÍAS JAVIER; FLICHMAN, DIEGO M

World Journal of Hepatology

Baishideng Publishing Group

Lugar: Beijing; Año: 2021 vol. 13 p. 1069 - 1078

1948-5182

The hepatitis C virus has a high mutation capacity that leads to the emergence ofresistance-associated substitutions (RAS). However, the consequence of resistanceselection during new direct-acting antiviral drug (DAA) treatment is not nece-ssarily the therapeutic failure. In fact, DAA treatment has shown a high rate (>95%) of sustained virological response even when high baseline RAS prevalencehas been reported. In the context of RAS emergence and high rates of sustainedviral response, the clinical relevance of variants harboring RAS is still contro-versial. Therefore, in order to summarize the data available in internationalguidelines, we have reviewed the clinical utility of testing RAS in the era of newpangenotypic DAA drugs.